Targeting interleukin-2 as a treatment for psoriasis.
Interleukin (IL)-2 is known to play a key role in the pathophysiology of psoriasis by activating T-cells. In recent years, therapies have been developed to specifically prevent T-cell activation by blocking the production of IL-2 or by inhibiting its action. These new therapies are discussed.